The Joint (JYNT) is a US-listed Healthcare company in Medical - Care Facilities with a market capitalization of
24M, trading at $8.71 on the NASDAQ. This SniperIQ fundamentals page covers The Joint's valuation (P/E 39.3x, P/B 8.0x), profitability (net margin 5.7%), revenue ($55M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap
24M
P/E (TTM)39.3x
Net Margin5.7%
Revenue (FY25)$55M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is The Joint's market cap?
The Joint (JYNT) has a market capitalization of approximately
24M, trading at $8.71 on the NASDAQ. Market cap moves with the live share price.
What is The Joint's P/E ratio?
The Joint's trailing twelve-month P/E ratio is 39.3x, with a price-to-book (P/B) of 8.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is The Joint?
The Joint runs a net profit margin of 5.7%, a gross margin of 79.9%, and an operating margin of 1.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does The Joint generate?
The Joint reported revenue of $55M for fiscal year 2025, with net income of
M and earnings per share (EPS) of 0.19. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does The Joint pay a dividend?
The Joint does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is The Joint financially healthy?
The Joint carries a debt-to-equity ratio of 0.13x and a current ratio of 1.61x, with a market beta of 1.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is The Joint a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For The Joint (JYNT) the key facts are: market cap
24M, P/E 39.3x, revenue $55M, 52-week range 7.5-11.75. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track The Joint's full fundamentals live
Get The Joint's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.